You are hereJune 1, 2021
AML Inhibits HSPC Function
Bone marrow failure, a characteristic clinical feature of acute myeloid leukemia (AML), causes significant morbidity and mortality. While previous work in mice suggested that AML cells functionally inhibit healthy hematopoietic stem and progenitor cells (HSPCs), researchers led by Thomas Schroeder (University of Duesseldorf, Germany) recently studied the infiltration of AML cells into the bone marrow using a human in vitro system. As reported in their recent STEM CELLS article, Jäger et al. establish that AML-secreted factors such as TGFβ1 inhibit essential functions of CD34+ HSPCs and suggest this pathway as a therapeutic target for AML patients.